No Data
No Data
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments
BriaCell Therapeutics (BCTX, BCT.TO) said Tuesday it has signed a clinical supply agreement with BeiGene (BGNE) to evaluate the safety and efficacy of its Bria-OTS immunotherapy, in combination with B
Express News | Briacell Announces Clinical Supply Agreement With Beigene for Bria-Ots™ First in Human Study
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
Study to evaluate the effects of Bria-OTS in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant
HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 price target.
BriaCell Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/24/2024 1185.44% HC Wainwright & Co. → $18 Reiterates Buy → Buy 12/28/2023 1185.44% HC Wainwright & Co.
No Data